Handbook of Stem Cell Transplantation and Cellular Therapy Management provides an evidence-based practical guide for clinicians and practitioners who treat cancer patients with these challenging and innovative techniques. The handbook begins with chapters on autologous transplantation for myeloma and lymphoma, and allogenic transplantation for leukemia, lymphoma and myelodysplastic syndrome. Further chapters cover the standards of care for managing adverse events related to acute graft-versus-host disease, chronic graft-versus-host disease, infections of bacterial, fungal, and viral nature, lymphoproliferative disease, pulmonary complications, renal complications, treatment of cancer relapse, as well as quality of life and long-term survivorship issues. Concluding chapters address new CAR-T therapies, including their mechanisms of action, indications, and unique associated toxicities such as cytokine release syndrome, in addition to a chapter dedicated to biostatistics and clinical trials. Throughout the book, extensive tables, flow diagrams and other figures highlight, simplify and illustrate key concepts.
Written by experienced clinicians at the world-renowned Dana Farber Cancer Center and Harvard Medical School in Boston and leading experts at other renowned institutions, this stem cell transplantation handbook combines the clinical knowledge, expertise and practical application of these potential life-saving cell therapies s in one quick, point-of-care reference . With real-world clinical vignettes interwoven among the chapters, this handbook is an essential resource for anyone managing patients being treated with stem cell transplantation or cellular therapies.
Provides latest insights and recommendations for managing challenging treatment complications and adverse events
Consolidates key information such as diagnosis criteria, disease staging, common complications, and more using detailed tables and helpful diagrams
Shares real-world clinical vignette examples which provide insight into clinical assessment, treatment, and management
Emphasizes patient management and best practices
Discusses short and long-term risks for stem cell transplantation and cellular therapy
Includes access to downloadable eBook for anytime access
In collaboration with Consulting Editor, Dr. Helen Boucher, Dr. Jo-Ann Young has put together a state-of the-art issue of the Infectious Disease Clinics of North America devoted to Management of Infectious Diseases in Stem Cell Transplantation and Hematologic Malignancy. Clinical review articles from expert authors are specifically devoted to the following topics, addressing both the stem cell transplant recipient and the hematologic malignancy patient: Chemotherapy Regimens for Hematologic Malignancies and Issues That Affect Infection; Stem Cell Transplantation Technical Issues That Affect Infection in The Recipient; Complications of Stem Cell Transplantation That Cause Infections; Antimicrobial Prophylaxis and Preemptive Agents and Regimens for the Prevention of Infection; Workup for Fever During Neutropenia; Herpesvirus Infections; Cytomegalovirus Infections; Respiratory Virus Infections; Other DNA Virus Infections; Bacterial Infections; Fungal Infections; Parasitic Infections; Vaccination; and Immunoglobulin Replacement. Readers will come away with the latest information they need to manage infections and improve outcomes in these patients.
Path-breaking innovations are about instigating fundamental changes in people, organizations, communities, and economies. They are complex, continuous, and evolutionary processes that take considerable time, resources, and the efforts of many individuals and organizations to be accomplished successfully. Representing distinct departures from existing practices, they differ from other types of innovation, such as product extensions and incremental improvements. By examining path-breaking innovation processes through in-depth analysis of several large-scale initiatives around the world, the authors explore how profound changes in product, process, and service can be explained and managed, and consider the practical implications for scientific, organizational, institutional, and political leaders concerned with channeling innovation toward economic growth.
In-depth analysis of science and technology initiatives at CERN-ATLAS, Airbus, and in stem cell research, the authors explore and illuminate how profound changes in product, process, and service can be explained and managed. Covering such issues as organizational culture, types of knowledge, and large-scale project management and resource distribution, the authors consider the practical implications of radical innovation for scientific, organizational, institutional, and political leaders concerned with channeling innovation toward economic growth.